{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Activity&page=103",
    "query": {
      "intervention": "High Activity",
      "page": 103
    },
    "page_size": 10
  },
  "pagination": {
    "page": 103,
    "page_size": 10,
    "total_count": 2761,
    "total_pages": 277,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Activity&page=104&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Activity&page=102&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-12T04:53:57.129Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07846020",
      "title": "Mechanistic Evaluation of Polypharmacy Effects for Pain",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lower Back Pain (CLBP)"
      ],
      "interventions": [
        {
          "name": "Within-subject test of blinded study medications (Placebo, Hydromorphone, Gabapentin)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 110,
      "start_date": "2027-01-15",
      "completion_date": "2032-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-11-12T04:53:57.129Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07846020"
    },
    {
      "nct_id": "NCT07215273",
      "title": "Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Invasive Mould Infection"
      ],
      "interventions": [
        {
          "name": "EL219",
          "type": "DRUG"
        },
        {
          "name": "Active Comparator- IV Antifungal (LAmB or voriconazole)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Elion Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2026-02-13",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-27",
      "last_synced_at": "2026-11-12T04:53:57.129Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Sacramento, California • Augusta, Georgia + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07215273"
    },
    {
      "nct_id": "NCT02462473",
      "title": "A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "Aripiprazole",
          "type": "DRUG"
        },
        {
          "name": "Olanzapine",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone",
          "type": "DRUG"
        },
        {
          "name": "Quetiapine",
          "type": "DRUG"
        },
        {
          "name": "Risperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 9,
      "start_date": "2015-05",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2017-03-29",
      "last_synced_at": "2026-11-12T04:53:57.129Z",
      "location_count": 3,
      "location_summary": "Torrance, California • Kissimmee, Florida • Conshohocken, Pennsylvania",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        },
        {
          "city": "Conshohocken",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02462473"
    },
    {
      "nct_id": "NCT02278328",
      "title": "MEG Study of Acute STX209 Effects in ASD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Autism Disorder"
      ],
      "interventions": [
        {
          "name": "STX209 (15mg)",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "STX209 (30mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Timothy Roberts",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "17 Years",
        "sex": "MALE",
        "summary": "14 Years to 17 Years · Male only"
      },
      "enrollment_count": 25,
      "start_date": "2016-02",
      "completion_date": "2019-09-27",
      "has_results": true,
      "last_update_posted_date": "2019-10-21",
      "last_synced_at": "2026-11-12T04:53:57.129Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02278328"
    },
    {
      "nct_id": "NCT00937365",
      "title": "Pregnancy-Related Low Back Pain and Complementary and Alternative Medicine (CAM) Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Low Back Pain"
      ],
      "interventions": [
        {
          "name": "Exercise",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Spinal Manipulation",
          "type": "PROCEDURE"
        },
        {
          "name": "Neuroemotional Technique (NET)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "PROCEDURE"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "20 Years to 49 Years · Female only"
      },
      "enrollment_count": 64,
      "start_date": "2009-07",
      "completion_date": "2012-04",
      "has_results": false,
      "last_update_posted_date": "2019-12-18",
      "last_synced_at": "2026-11-12T04:53:57.129Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00937365"
    },
    {
      "nct_id": "NCT04644029",
      "title": "Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-I",
        "Human Immunodeficiency Virus Type 1",
        "Prophylaxis"
      ],
      "interventions": [
        {
          "name": "Islatravir",
          "type": "DRUG"
        },
        {
          "name": "Placebo to FTC/TDF",
          "type": "DRUG"
        },
        {
          "name": "FTC/TDF",
          "type": "DRUG"
        },
        {
          "name": "Placebo to ISL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "16 Years to 45 Years · Female only"
      },
      "enrollment_count": 730,
      "start_date": "2021-02-24",
      "completion_date": "2024-06-11",
      "has_results": true,
      "last_update_posted_date": "2026-02-04",
      "last_synced_at": "2026-11-12T04:53:57.129Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04644029"
    },
    {
      "nct_id": "NCT04100057",
      "title": "Sleep Disturbance and Emotion Regulation Brain Dysfunction as Mechanisms of Neuropsychiatric Symptoms in Alzheimer's Dementia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Alzheimer Disease",
        "Mild Cognitive Impairment",
        "Neuropsychiatric Symptoms",
        "Sleep Disturbance"
      ],
      "interventions": [
        {
          "name": "Cognitive Behavioral Therapy for Insomnia (CBT-I)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Desensitization Therapy for insomnia (DT-I)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 150,
      "start_date": "2021-08-31",
      "completion_date": "2026-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-11-12T04:53:57.129Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04100057"
    },
    {
      "nct_id": "NCT05419128",
      "title": "Family-focused vs. Drinker-focused Smartphone Interventions to Reduce Drinking-related Consequences of COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Alcohol Use Disorder",
        "Family Members",
        "Behavior, Addictive"
      ],
      "interventions": [
        {
          "name": "PartnerCHESS",
          "type": "BEHAVIORAL"
        },
        {
          "name": "ACHESS",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 398,
      "start_date": "2022-04-06",
      "completion_date": "2024-07-17",
      "has_results": true,
      "last_update_posted_date": "2026-02-19",
      "last_synced_at": "2026-11-12T04:53:57.129Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05419128"
    },
    {
      "nct_id": "NCT02176902",
      "title": "Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Adenocarcinoma of the Prostate",
        "Stage I Prostate Cancer",
        "Stage IIA Prostate Cancer",
        "Stage IIB Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "behavioral dietary intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "omega-3 fatty acid",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "80 Years",
        "sex": "MALE",
        "summary": "50 Years to 80 Years · Male only"
      },
      "enrollment_count": 107,
      "start_date": "2014-11-01",
      "completion_date": "2026-11-01",
      "has_results": false,
      "last_update_posted_date": "2025-02-10",
      "last_synced_at": "2026-11-12T04:53:57.129Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02176902"
    },
    {
      "nct_id": "NCT04625595",
      "title": "Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type1 Diabetes"
      ],
      "interventions": [
        {
          "name": "350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule",
          "type": "DRUG"
        },
        {
          "name": "700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule",
          "type": "DRUG"
        },
        {
          "name": "1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule",
          "type": "DRUG"
        },
        {
          "name": "1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Immunomolecular Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 30,
      "start_date": "2020-11-09",
      "completion_date": "2021-07-31",
      "has_results": false,
      "last_update_posted_date": "2021-08-25",
      "last_synced_at": "2026-11-12T04:53:57.129Z",
      "location_count": 3,
      "location_summary": "Chula Vista, California • Aurora, Colorado • Renton, Washington",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Renton",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04625595"
    }
  ]
}